• Explore /
  • Poster
  • / ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.

ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.

Abstract Poster

Authors

Amit Oza

Amit M. Oza

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Amit M. Oza , Domenica Lorusso , Ana Oaknin , Tamar Safra , Elizabeth Swisher , Igor Bondarenko , Tomasz Huzarski , Jaroslav Klat , Róbert Póka , Luciana Spillari Viola , Chris Tankersley , Lara Maloney , Sandra Goble , Caro Unger , Heidi Giordano , Rebecca Sophie Kristeleit

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02855944

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS5603)

DOI

10.1200/JCO.2017.35.15_suppl.TPS5603

Abstract #

TPS5603

Poster Bd #

423b

Abstract Disclosures

Similar Posters

First Author: Charles J. Ryan

First Author: Charles J. Ryan

First Author: Benedito A. Carneiro

First Author: Wassim Abida